Abstract
Background: Fibroblast growth factor 23 (FGF23) has been associated with death in dialysis patients. Since FGF23 shares structural features with FGF19 subfamily members that exert hormonal control of fat mass, we hypothesized that high circulating FGF23 concentrations would be associated with the development of a uremic lipid profile and lower body mass index (BMI). Methods: This study was conducted among 654 patients receiving chronic hemodialysis. C-terminal FGF23 concentrations were measured in stored plasma samples. Linear regression was used to examine the cross-sectional associations of plasma FGF23 concentrations with BMI, total cholesterol (TC), low-density lipoprotein-cholesterol (LDLC), high-density lipoprotein-cholesterol (HDL-C) and triglycerides. Cox proportional hazard models were used to examme the association between FGF23 concentrations and all-cause mortality. Results: Participants had a mean age of 60 +/- 11 years and a median (IQR) FGF23 concentration of 4,212 (1,411-13,816) RU/ml. An increase per SD in log(10) FGF23 was associated with lower BMI (beta = -1.11; p = 0.008), TC (beta = -6.46; p = 0.02), LDL-C (beta = -4.73; p = 0.04) and HDL-C (beta = -2.14; p = 0.03); after adjusting for age, gender, race, cardiovascular risk factors, serum albumin, markers of mineral metabolism, and use of lipid-lowering drugs. The association of FGF23 with death was attenuated after adjustment for HDL-C (HR of highest quartile 1.53, 95% Cl 1.06-2.20 compared to lowest quartile). Conclusion: These results indicate that higher plasma FGF23 levels are associated with lower BMI and dyslipidemia in dialysis patients. The association between FGF23 and death may be mediated through unexplored metabolic risk factors unrelated to mineral metabolism. Copyright (C) 2013 S. Karger AG, Basel